Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
Surgery isn't always the final chapter for pNET patients. A new retrospective study found that nearly 20% of patients with non-metastatic pancreatic neuroendocrine tumors (pNETs) developed metastatic disease within about 4 years of surgical resection. High tumor grade, larger tumor size, and lymph node involvement were the strongest predictors of recurrence — highlighting the critical need for long-term post-surgical surveillance.
For patients with pancreatic neuroendocrine tumors (pNETs), a successful resection may not mean the disease is gone for good. A retrospective study presented at the 2026 NANETS Multidisciplinary NET Medical Symposium found that nearly 1 in 5 patients who had no evidence of metastasis at the time of surgery went on to develop metastatic disease — with a median time to metastasis of just 42 months post-resection.
The study drew on data from 208 patients treated at a single institution between 2000 and 2024. Among those who were initially non-metastatic (M0), the liver was the most common site of new metastases (82.6%), followed by retroperitoneal lymph nodes (26.1%). Both initial and late metastatic disease significantly worsened overall survival compared to remaining M0.
Key Takeaways
Why it matters: These findings reinforce that pNET patients — even those who appear cancer-free after surgery — need rigorous, long-term follow-up. Identifying high-risk features early could help clinicians tailor surveillance strategies and intervene sooner if metastasis occurs.
